Technologies
Counseling & Strategic Advice
IP Transactions
Litigation
PTAB Proceedings
Technology Transfer
Trademark & Designs
U.S. Patent Procurement (Application Drafting & Prosecution)Fast Facts
Law Firm
Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.
History
1968
Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.
Global Reach
Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.
ACCOLADES
Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.
Career
From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.
GET In Touch
Patent Forms
The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.
Our Blogs
LATEST NEWS
PUBLICATIONS
by Sana Tahir, Law Clerk and Andrew Ollis, Partner
Events
May 7, 2026 at 10:30am and 8:00pm
Blogs
Publications
SOVEREIGN IMMUNITY AND IPR'S: AND NOW, THE REST OF THE STORY
Radio great Paul Harvey would always leave listeners hanging during his broadcast, then return from a commercial with "the rest of the story". Previously, I wrote on the Federal Circuit ruling with respect to Tribal Immunity (https://www.oblon.com/publications/tribal-immunity-in-ipr-is-dealt-a-death-blow-by-the-federal-circuit). At the end of that article I stated: "I note, however, that in the final sentence of their analysis, the Federal Circuit explicitly stated that this decision did NOT address whether there is any reason to treat state sovereign immunity differently with respect to IPR proceedings. That will remain to be seen…"
Oracle v. Google
Brain Darville wrote an article for Intellectual Property magazine's June issue entitled "Oracle v. Google."
Intellectual Property Magazine - June Edition
Written Description In Provisional Application: Perdue Pharma L.P. v. Andrei Iancu.
Amneal Pharmaceuticals, LLC. ("Amneal") filed two petitions for inter partes review of claims 1–13 and 16–19 of U.S. Patent No. 9,034,376 ("the '376 patent") of Purdue Pharma L.P., P.F. Laboratories, Inc. and Purdue Pharmaceuticals L.P. ("Purdue").
What You Say Can Hurt You
Often in writing applications there is a tendency to denigrate prior art techniques. This is not risk free as the patentee in Nuvo Pharmaceuticals (Ireland) v. Dr. Reddy's Laboratories, Inc. (Fed. Cir. May 15, 2019) discovered.
Patent Strategy and the Internet of Medical Things
James Love wrote an article entitled "Patent Strategy and The Internet of Medical Things," featured in Med Device Online.
Med Device Online
PTAB Issues Two New Precedential Opinions On Discretion to Deny Review – Implications for Generics
The PTAB designated two decisions as precedential this week (in addition to several in previous weeks), both relevant to the Board's discretion to deny review. These cases illustrate that the PTO is in the process of designating precedential opinions on a number of issues, in line with revised Standard Operating Procedure 2 for designating precedential and informative decisions. See my previous posts on other recent precedential decisions here and here.
AI: IP Policy Consideration
On January 31, 2019, the U.S. Patent and Trademark Office (US PTO) organized a full-day event titled "Artificial Intelligence: Intellectual Property Policy Considerations" which included numerous speakers such as government administrators, academics, industry leaders, and practitioners. One of the many topics discussed the challenges of patenting AI, implications of advancing AI technology on IP laws such as copyright and trademarks, and perspectives on AI policies around the world. In the following slides, some of the topics are summarized with highlights and comments: (i) focus areas of the current administration for promoting AI R&D in US, (ii) key aspects of AI and strategies for preparing AI related patent applications, and (iii) perspectives on AI policies in EU, China, Singapore, and Japan.
USPTO Event -
Oracle v. Google - An Epic Software Battle
Business Law Today
